Cadila Healthcare has received US Food and Drug Administration (USFDA) clearance for its Gujarat plant after an inspection. The USFDA inspected company’s Moraiya facility from February 6, 2017 to February 15, 2017. At the end of the inspection, no observation (483) has been issued.
Earlier, USFDA had issued a warning letter to the Cadila’s facility at Moraiya in Gujarat for breach of good manufacturing practices.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.60 |
| Dr. Reddys Lab | 1237.20 |
| Cipla | 1235.85 |
| Zydus Lifesciences | 941.30 |
| Lupin | 2323.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: